The Critical Role of JDRF in Shaping Type 1 Diabetes Research

Type 1 diabetes (T1D) is a chronic autoimmune condition that affects millions worldwide, demanding lifelong management and posing significant health risks. At the forefront of the fight against T1D stands JDRF (formerly the Juvenile Diabetes Research Foundation), a global organization that has transformed the landscape of T1D research and technology development. JDRF’s core mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. Advocacy for increased funding is central to this mission, as financial resources determine the pace and scope of scientific discovery. Without sustained and expanded investment, promising research pipelines stall, and innovative technologies remain out of reach for those who need them most.

JDRF’s advocacy work is not just about dollars—it’s about prioritizing T1D on national and global health agendas. Through strategic campaigns, policy engagement, and partnerships, JDRF ensures that T1D research receives the attention and funding it deserves. This article explores how JDRF’s relentless advocacy drives increased funding, the impact of that funding on technology and treatment development, and the future of T1D research that this support makes possible.

The Funding Landscape for Type 1 Diabetes Research

Research funding for T1D comes from multiple sources: federal governments, private foundations, pharmaceutical companies, and individual donors. Yet, despite the growing prevalence of T1D—with incidence rates rising by 2–3% annually in many countries—funding has historically lagged behind that for other chronic diseases. JDRF addresses this gap by amplifying the voice of the T1D community and demonstrating the urgent need for investment.

Government Funding and the Special Diabetes Program

In the United States, the Special Diabetes Program (SDP) has been a cornerstone of federal T1D research funding. Administered through the National Institutes of Health (NIH), the SDP has provided hundreds of millions of dollars since its inception in 1997. JDRF has been instrumental in advocating for its renewal and expansion, organizing advocacy days on Capitol Hill and mobilizing grassroots supporters to contact their representatives. Without persistent advocacy, the SDP might have expired multiple times. JDRF’s success here underscores how sustained engagement with policymakers secures critical resources.

Beyond the SDP, JDRF works to ensure T1D is reflected in broader NIH budget allocations. The organization provides expert testimony, publishes white papers, and builds coalitions with other disease advocacy groups to argue for increased overall research funding. This approach recognizes that T1D competes with other health priorities, and only strong advocacy can keep it visible.

Private Sector and Philanthropic Investment

While government funding is essential, JDRF also drives investment from private sources. The organization partners with biotech companies to fund early-stage research, provides venture philanthropy capital through its T1D Fund, and encourages individual and corporate donations. The JDRF T1D Fund has invested over $100 million in companies developing T1D therapies, leveraging additional private capital. This model de-risks innovation, attracting partners who might otherwise shy away from the high costs of drug and device development.

Philanthropic funding allows JDRF to pursue high-risk, high-reward projects that may not fit traditional grant criteria. For example, projects exploring beta cell regeneration or immune tolerance require years of basic research before clinical translation. Private donations provide the flexibility needed to sustain these long-term efforts. JDRF’s advocacy thus extends beyond lobbying—it includes storytelling that inspires donors to invest in a future without T1D.

JDRF’s Advocacy Initiatives: A Multi-Pronged Approach

JDRF’s advocacy is not limited to requesting money; it is a sophisticated operation that combines grassroots mobilization, policy expertise, and media outreach. The organization ensures that policymakers at all levels understand the human and economic costs of T1D, as well as the potential returns on research investment.

Grassroots Advocacy and Community Engagement

JDRF’s network of volunteers and local chapters is the foundation of its advocacy power. The annual "JDRF Advocacy Day" brings hundreds of T1D families to Washington, D.C., to meet with members of Congress. Participants share personal stories, which are far more persuasive than statistics alone. JDRF also trains advocates through its "JDRF Advocacy Ambassador" program, equipping them with tools to speak effectively about research needs.

Digital campaigns complement in-person efforts. JDRF uses email, social media, and webinars to mobilize supporters for timely actions—such as urging Congress to co-sponsor a funding bill or to oppose cuts to the NIH budget. By making advocacy accessible, JDRF ensures that the T1D community’s voice is heard consistently.

Policy Engagement and Legislative Strategy

On the policy front, JDRF maintains a full-time government relations team that works with congressional staff, federal agencies, and international bodies. The organization provides expert testimony, submits formal comments on proposed regulations, and drafts model legislation. For instance, JDRF advocated for the Medicare CGM Access Act and the Better Care for People with Complex Needs Act, both of which improved coverage for T1D technologies.

JDRF also engages with the National Institutes of Health and the Food and Drug Administration to ensure that research priorities align with patient needs. The organization participates in NIH study sections and FDA advisory committees, offering the patient perspective. This deep integration into the policy ecosystem means that JDRF influences not just how much funding is allocated, but how it is spent.

Building Partnerships and Coalitions

No single organization can drive change alone. JDRF collaborates with other disease advocacy groups—such as the American Diabetes Association and the Endocrine Society—as well as industry partners, to amplify its message. The JDRF Industry Consortium brings together pharmaceutical and device companies to pre-competitively share data and accelerate development. These partnerships create a unified front that makes it harder for policymakers to ignore T1D.

International advocacy is also a priority. JDRF has affiliates in countries like the UK, Australia, and Canada, where it works with local health ministries to secure research funding and improve access to technology. The global nature of T1D means that breakthroughs anywhere benefit everyone, and JDRF’s international presence ensures that advocacy efforts are coordinated across borders.

Advancements in T1D Technology Enabled by Increased Funding

The most visible result of increased funding is the rapid evolution of diabetes management technology. Devices that were once science fiction are now standard of care, dramatically improving quality of life for people with T1D. JDRF has directly funded many of these innovations, often providing the early capital that de-risked development.

Continuous Glucose Monitors (CGMs)

Continuous glucose monitors, such as the Dexcom G6 and Abbott FreeStyle Libre, have replaced fingerstick testing for many users. These devices provide real-time glucose readings, trend arrows, and alarms for high and low blood sugar. JDRF funded early clinical trials of CGM technology and advocated for Medicare coverage, which was a game-changer for older adults with T1D. The result: CGMs are now available to a broader population, reducing the burden of constant monitoring.

Insulin Pumps and Automated Delivery Systems

Insulin pumps have evolved from simple continuous infusion devices to sophisticated systems that integrate with CGMs. The hybrid closed-loop, or artificial pancreas, systems like the Tandem t:slim X2 with Control-IQ and the Medtronic MiniMed 780G automatically adjust insulin delivery based on glucose readings. JDRF co-funded the early development of these algorithms through its Artificial Pancreas Project, which began in 2006. Since then, JDRF’s advocacy for regulatory flexibility and insurance coverage has accelerated market entry.

Future Technologies in the Pipeline

Funding continues to drive innovation. Next-generation technologies include implantable CGMs, smart insulin pens with dose tracking, and fully automated closed-loop systems that require no user input. JDRF is also investing in smart insulin—insulin that becomes active only when blood sugar is high—and glucose-responsive insulin. These approaches aim to reduce the cognitive load of diabetes management and improve glycemic control.

  • Implantable CGM sensors that last months or years, eliminating frequent sensor changes.
  • Multi-hormone artificial pancreas systems that deliver both insulin and glucagon for better glucose stability.
  • Digital health platforms that aggregate device data and provide actionable insights to patients and clinicians.

Each of these advances relies on sustained research funding. Without JDRF’s advocacy, many of these developments would be delayed or never reach the market.

The Pathway to a Cure: Research Breakthroughs Made Possible by Advocacy

While technology improves daily life, JDRF’s ultimate goal remains a cure. Increased funding has opened multiple fronts in the search for a cure, from immune modulation to beta cell replacement. JDRF focuses its investments on the most promising research areas, ensuring that donor dollars have maximum impact.

Immune System Modulation

T1D occurs when the immune system attacks insulin-producing beta cells in the pancreas. Therapies that can halt or reverse this attack hold the key to prevention and early-stage cures. JDRF has funded clinical trials of drugs like teplizumab, an anti-CD3 antibody that can delay the onset of T1D by several years. In 2022, teplizumab became the first drug approved to delay T1D, a milestone made possible by early JDRF investment and advocacy for regulatory pathways for prevention treatments.

Other immune-modulating approaches under investigation include antigen-specific therapies, regulatory T cell therapy, and checkpoints that reset the immune system. JDRF’s support for the Immune Tolerance Network and other consortia has accelerated these studies.

Beta Cell Regeneration and Replacement

For people who have already lost beta cell function, regenerating or replacing those cells is a curative strategy. JDRF funds research into stem cell-derived beta cells, as well as methods to protect transplanted cells from immune attack. The organization was an early backer of ViaCyte (now part of Vertex Pharmaceuticals), which developed an implantable device containing stem cell-derived islet cells. Preliminary results show that these cells can produce insulin in patients, and ongoing trials aim to improve the durability and safety of the implants.

Gene editing tools like CRISPR offer another avenue. JDRF has funded projects that use CRISPR to modify immune cells or create beta cells that are invisible to the immune system. While still in preclinical stages, these approaches hold immense promise.

Complication Prevention and Treatment

Curing T1D also means preventing or reversing its complications, such as retinopathy, neuropathy, nephropathy, and cardiovascular disease. JDRF funds research into biomarkers that predict complication risk, as well as therapies that block the pathways leading to tissue damage. For example, studies on the role of advanced glycation end-products (AGEs) have led to drugs that prevent their formation. Better control through advanced technology already reduces complication rates, but research continues to address the damage that occurs even with good management.

Challenges and the Road Ahead

Despite remarkable progress, significant challenges remain. Funding is never guaranteed; each budget cycle brings new threats to research appropriations. The Special Diabetes Program must be renewed every few years, and each renewal requires intense advocacy. Political shifts can deprioritize T1D, and the competition for NIH dollars is fierce.

Another challenge is translating research into accessible treatments. Even when therapies are developed, they can be expensive or slow to reach patients. JDRF advocates for insurance coverage and fair pricing, recognizing that a cure is only meaningful if it is available to everyone. The organization works with health plans and pharmacy benefit managers to ensure that new technologies are covered.

Equity is also a growing concern. T1D disproportionately affects certain populations, and disparities in access to technology and care remain. JDRF has launched initiatives to address health equity, including funding research into community-based interventions and advocating for policies that reduce barriers. Future advocacy must ensure that increased funding benefits all people with T1D, not just those with resources.

The road ahead is promising but requires vigilance. JDRF’s advocacy must adapt to new challenges, such as the rise of misinformation about diabetes treatments and the need for global cooperation in an increasingly interconnected world. By staying nimble and inclusive, JDRF can continue to drive funding and innovation.

How to Support JDRF’s Advocacy Mission

Individuals can make a difference by joining JDRF’s advocacy network. Sign up for action alerts on the JDRF website to receive notifications about upcoming votes, hearings, or public comment periods. Donating to JDRF’s research fund directly supports the discovery pipeline, while contributions to the T1D Fund fuel entrepreneurial ventures.

Participating in local JDRF events—such as walks, galas, and bike rides—raises funds and visibility. Perhaps most importantly, sharing your story humanizes the cause and strengthens the case for increased funding. Whether you have T1D yourself, care for a loved one, or simply want to see an end to this disease, your voice matters.

Learn more about JDRF’s current advocacy priorities at JDRF Advocacy and explore research updates at JDRF Research. For a comprehensive overview of the Special Diabetes Program, see the NIH Special Diabetes Program page. To track the latest in artificial pancreas technology, consult the FDA’s artificial pancreas device page.

JDRF’s advocacy for increased funding is not just about money—it is about hope. Every dollar invested in T1D research brings us closer to a world where no one has to count carbohydrates, inject insulin, or fear a sudden low. With continued support, that world is within reach.